EUVIMEDEUVIMED entdecken
Crossref

Treatment outcomes of esophageal squamous cell carcinoma with cM1 lymph node without organ metastasis

Manato Ohsawa, Yoichi Hamai iD, Manabu Emi, Yuta Ibuki, Tomoaki Kurokawa, Ryosuke Hirohata, Nao Kitasaki iD, Morihito Okada iD

Diseases of the Esophagus · 2025

DOI: 10.1093/dote/doaf095 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diseases of the Esophagus, 2025. Verfasst von Manato Ohsawa und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Oncology, Hiroshima University, Hiroshima 734-0037, Japan. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Lymph Nodes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Stage IVB esophageal cancer typically has a poor prognosis; patients with non-regional lymph-node metastasis (cM1 LYM) but no organ metastasis generally fare better. However, comprehensive reports on treatment outcomes are limited. We included 158 patients with esophageal squamous cell carcinoma (ESCC) and cM1 LYM without organ metastasis treated at our institute between October 2006 and November 2022; their treatment outcomes were assessed, and prognostic factors were evaluated. The 3-year overall survival (OS) rates for all patients and those treated with surgery, chemoradiotherapy, chemotherapy, or palliative radiotherapy were 43.7%, 60.7%, 38.5%, 22.4%, and 20.0%, respectively. Surgery or chemoradiotherapy significantly improved OS compared to chemotherapy. Univariate and multivariate analyses identified significant OS prognostic factors: Eastern Cooperative Oncology Group performance status (ECOG PS) (1/2 vs. 0), type of cM1 LYM areas (two areas vs. thoracic area), and clinical response (stable/progressive disease vs. complete/partial response). In the subgroup receiving surgery or chemoradiotherapy, both analyses identified ECOG PS (1/2 vs. 0) and clinical response (stable/progressive disease vs. complete/partial response) as prognostic factors for OS. ESCC patients with cM1 LYM without organ metastasis had relatively good survival; those with good PS and a favorable clinical response especially achieved long-term survival. Because patients who underwent surgery or chemoradiotherapy had significantly better OS than those treated with chemotherapy, appropriate localized treatment might be necessary even in these cases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal Squamous Cell CarcinomaEsophageal NeoplasmsLymph NodesHumansMaleFemaleMiddle AgedAgedLymphatic MetastasisTreatment OutcomeChemoradiotherapyPrognosisRetrospective StudiesEsophagectomySurvival RateNeoplasm StagingAdultPalliative CareAged, 80 and over

Stichwörter der Autor:innen

esophageal squamous cell carcinomalymph-node metastasismetastasisprognosis

Autor:innen und Institutionen

  • Department of Surgical Oncology, Hiroshima University, Hiroshima 734-0037, Japan.

ORCID-Profile: Yoichi Hamai, Nao Kitasaki, Morihito Okada

Zitieren

APA

Ohsawa, M., Hamai, Y., Emi, M., Ibuki, Y., Kurokawa, T., Hirohata, R., Kitasaki, N., & Okada, M. (2025). Treatment outcomes of esophageal squamous cell carcinoma with cM1 lymph node without organ metastasis. Diseases of the Esophagus. https://doi.org/10.1093/dote/doaf095

Vancouver

Ohsawa M, Hamai Y, Emi M, Ibuki Y, Kurokawa T, Hirohata R, et al. Treatment outcomes of esophageal squamous cell carcinoma with cM1 lymph node without organ metastasis. Diseases of the Esophagus. 2025. doi:10.1093/dote/doaf095

BibTeX
@article{Ohsawa2025,
  author = {Ohsawa, Manato and Hamai, Yoichi and Emi, Manabu and Ibuki, Yuta and Kurokawa, Tomoaki and Hirohata, Ryosuke and Kitasaki, Nao and Okada, Morihito},
  title = {Treatment outcomes of esophageal squamous cell carcinoma with cM1 lymph node without organ metastasis},
  journal = {Diseases of the Esophagus},
  year = {2025},
  doi = {10.1093/dote/doaf095}
}
Kostenlos starten →